Navigation Links
Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
Date:8/23/2007

SAN DIEGO, Aug. 23 /PRNewswire/ -- eBioscience Corporation announced the appointment of Todd R. Nelson, Ph.D., to CEO of eBioscience, effective immediately. Dr. Nelson comes to eBioscience from Invitrogen Corporation where he was Vice President, Global Corporate Development.

Dr. Nelson will assume the role of CEO and Lily Lai, eBioscience's founder, will remain as President during a transition period. Nelson will also join eBioscience's Board of Directors.

Dr. Nelson commented: "I'm very excited about joining a fast growing company with the reputation and potential of eBioscience. The company's breakthrough products and enabling technologies are critical to the future of biotechnology and life science research."

Dr. Brian Seed, the Lead Director on eBioscience's Board of Directors, commented: "Todd has exceptional technical, financial and operating experience, and the energy and strategic vision to lead eBioscience through its next stage of growth."

Seed continued: "During Lily's tenure as President, eBioscience has grown from a start-up enterprise to a fast growing, profitable company that now has more than 1,000 products on the market, and a strong brand within the life science research community. We are grateful for her many contributions to eBioscience."

Todd R. Nelson was named Vice President Global Corporate Development and Strategy of Invitrogen Corporation in 2005. In addition to being responsible for mergers and acquisitions functions globally, Nelson held primary responsibility for the development and implementation of both corporate and divisional strategies for the organization on a world wide basis. Prior to that, he was Managing Director and Head, Global Life Sciences Corporate Strategy and Research at RBC Capital Markets, and First Vice President, Global Corporate Strategy and Economics at Merrill Lynch in New York.

Dr. Nelson has been a visible figure within the Life Sciences industry. During his more than 15 year tenure in the industry he has been responsible for the design and implementation of numerous corporate and operating strategies for various companies. In addition, he led the underwriting activities for more than 30 IPOs and has been involved in numerous value creating mergers and acquisitions, together totaling more than $7 billion. He has been a founder of several biotechnology companies and currently serves on the Board of Directors of Lokoya Capital Partners, LLC. Fluoropharma, Inc., and Blue Heron Biotechnologies, Inc.

Dr. Nelson has a Ph.D. from the University of Minnesota in molecular pathology and received advanced training as a senior fellow in clinical chemistry and molecular diagnostics at Mayo Clinic. Dr. Nelson received his MBA from the Carlson School of Business.

About eBioscience

eBioscience, headquartered in San Diego, California provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide. The company provides essential life science technologies for disease research and drug discovery. For more information, visit http://www.ebioscience.com.


'/>"/>
SOURCE eBioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs)
2. Bruce Maas named CIO at UW-Milwaukee
3. Three finalists named for UW-Madison CIO
4. Eight lawmakers named to Speakers IT task force
5. Hospital named for Madame Curie installs TomoTherapy system
6. Two UW-Madison professors named to National LambdaRail Networking Research Council
7. UW researcher named top innovator
8. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
9. Inacom named Microsofts favorite learning solutions partner of the year
10. Five Wisconsin CIOs named top in nation
11. Deltanoid named to top-15 list of biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):